59985-21-6

Basic information

• Product Name: [[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-phosphinic acid
• Synonyms: [[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-phosphinic acid;Diquafosol;Diquafosol [inn:ban];Diquafosol [inn];Kpy 998;p1,p4-Bis(5'-uridyl) tetrahydrogen tetraphosphate;Unii-7828vc80fj;P1,P4-Diuridine 5'-Tetraphosphate
• CAS NO: 59985-21-6
• Molecular Formula: C18H26N4O23P4
• Molecular Weight: 790.31
• Product Categories: Agonists;Bases & Related Reagents;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals
• Mol File: 59985-21-6.mol
• Article Data: 10

Chemical Properties

• Appearance: /
• Density: 2.044g/cm³
• Refractive Index: 1.66
• PKA: 0.40±0.50(Predicted)
• CAS DataBase Reference: [[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-phosphinic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-phosphinic acid(59985-21-6)
• EPA Substance Registry System: [[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxy-phosphinic acid(59985-21-6)

Safety Data

• Hazardous Substances Data: 59985-21-6(Hazardous Substances Data)

Usage

Uses

Diquafosol is a dinucleoside derivative of uridine that acts as a selective P2Y2 receptor agonist. Diquafosol is used as a therapeutic agent in the treatment of dry eye syndrome.

Definition

ChEBI: A pyrimidine ribonucleoside 5'-tetraphosphate compound having 5'-uridinyl residues at the P1- and P4-positions.

InChI:InChI=1/C18H26N4O23P4/c23-9-1-3-21(17(29)19-9)15-13(27)11(25)7(41-15)5-39-46(31,32)43-48(35,36)45-49(37,38)44-47(33,34)40-6-8-12(26)14(28)16(42-8)22-4-2-10(24)20-18(22)30/h1-4,7-8,11-16,25-28H,5-6H2,(H,31,32)(H,33,34)(H,35,36)(H,37,38)(H,19,23,29)(H,20,24,30)/t7-,8-,11-,12-,13-,14-,15-,16-/m1/s1

Upstream product

• 65062-82-0 di-(1-imidazolyl)diphosphonic acid 
• 3387-36-8 disodium uridine-5'-monophosphate 
• 121-44-8 triethylamine 
• 647032-50-6 UMP triethylammonium salt 
• 102-82-9 tributyl-amine 
• 1476-50-2 uridine 5'-triphosphate trisodium salt 
• 58-97-9 5'-Uridylic Acid 
• 63-39-8 UTP 
• 58-98-0 UDP 

Relevant articles and documents

Preparation method of P,P-di(uridine 5'-)tetraphosphate

The invention relates to the technical field of medicine synthesis, in particular to a preparation method of a P,P-di(uridine 5'-)tetraphosphate. The preparation method of P,P-di(uridine 5'-)tetraphosphate as shown in a formula I comprises the step that a phosphoryl imidazole active compound as shown in a formula II or a formula III and a phosphoric acid active compound or a salt thereof undergo a reaction in an aqueous or hydrophilic solvent in the presence of gadolinium (III) ions or samarium (III) ions, so that the P,P-di(uridine 5'-)tetraphosphate (as shown in the description) is prepared.

Method for Preparing a Dinucleoside Polyphosphate Compound

The present invention relates to a method of preparing dinucleoside polyphosphate with high purity at a high yield, salt thereof, and a hydrate thereof. The method of preparing dinucleoside polyphosphate according to the present invention is performed at an environmentally-friendly reaction condition without complicated processes, and thereby can be usefully applied for the industrial mass-production.

High-purity P1,P4-bis(uridine-5'-tetraphosphoric acid) salt preparation method

The invention provides a P1,P4-bis(uridine-5'-tetraphosphoric acid) salt preparation method. The method includes: subjecting tributylamine salt of UTP to action of carbodiimide condensing agents; subjecting synthesis with excessive tributylamine salt of UMP to obtain P1,P4-bis(uridine-5'-tetraphosphoric acid); performing anion exchange resin gradient elution without water concentration, diluting, performing anion exchange resin elution again, and salifying and refining to obtain P1,P4-bis(uridine-5'-tetraphosphoric acid) salt. The method has advantages that the production cycle can be shortened remarkably, and products in medicinal purity can be obtained by preparation.